Genetically increasing omega-3 fatty acid production improves glucose balance in obese mice

A new study from researchers at Laval University in Quebec, Canada, shows that genetically increasing omega-3 fatty acid production, without direct gut microbiota contact, improves the balance of insulin and glucagon (glucose balance) in obese mice. Omega-3 fatty acids reduce fat deposits in the liver by interacting with gut microbiota during the digestion process. Augmenting omega-3 fatty acid liver content, in turn, increased levels of omega-3–derived mediators, which could play a critical role in reducing liver fat storage and chronic inflammation.

We were trying to determine what role the gut microbiota plays in omega-3 fatty acid-related metabolic improvements such as plasma glucose and insulin, gut health and liver function."

André Marette, PhD, lead author of the study

Fatty liver disease is increasingly being diagnosed and associated with comorbidities such as diabetes and heart disease. The goal is to reduce fatty liver disease and related comorbidities by reducing chronic inflammation and the amount of liver fat deposits.

Source:
Journal reference:

Daniel, N., et al. (2022) Comparing transgenic production to supplementation of ω-3 PUFA reveals distinct but overlapping mechanisms underlying protection against metabolic and hepatic disorders. Function. doi.org/10.1093/function/zqac069.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mursla Bio's EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024